ES2190221T3 - Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas. - Google Patents

Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.

Info

Publication number
ES2190221T3
ES2190221T3 ES99927711T ES99927711T ES2190221T3 ES 2190221 T3 ES2190221 T3 ES 2190221T3 ES 99927711 T ES99927711 T ES 99927711T ES 99927711 T ES99927711 T ES 99927711T ES 2190221 T3 ES2190221 T3 ES 2190221T3
Authority
ES
Spain
Prior art keywords
alkyl
formula
atom
substituted
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99927711T
Other languages
English (en)
Inventor
Siavosh Mahboobi
Wall Sabine De
Herwig Pongratz
Alfred Popp
Harald Hufsky
Frank-D Bohmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19838506A external-priority patent/DE19838506C2/de
Application filed by Zentaris AG filed Critical Zentaris AG
Application granted granted Critical
Publication of ES2190221T3 publication Critical patent/ES2190221T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos de fórmula general I: **(Fórmula)** en la que Z es un grupo de fórmula general (II) **(Fórmula)** en la que B, B¿ pueden ser un átomo de carbono, nitrógeno, oxígeno o azufre y los sistemas de anillo F y G pueden ser, independientemente entre sí, anillos penta y hexagonales tanto saturados como insaturados, X representa un grupo de fórmula general III o IV, **(Fórmula)** en la que A puede ser un átomo de N, O, S, l y n pueden tomar los números de 0 a 6, m los números 1 y 2, así como R14 y R15 conjuntamente forman un átomo de oxígeno o R14 significa un grupo hidroxilo y R15 un átomo de hidrógeno, o R14 y R15 significan átomos de hidrógeno, y en la que R16 significa un átomo de hidrógeno, un resto alquilo o arilo, un resto alquilo o arilo sustituido con halógeno, amino o azido, un resto alquiloximetilo o alquiloximetilo sustituido, R2 y R13 forman conjuntamente una unión de fórmula general V o VI **(Fórmula)** en las que el enlace de trazos discontínuos significa un enlace doble o sencillo, A y R16 poseen los mismos significados que anteriormente y o puede adoptar los números 1 y 2, R2 y R13 significan restos iguales o distintos de fórmula general VII o átomos de hidrógeno, **(Fórmula)** en la que el enlace de trazos discontínuos significa un enlace doble o sencillo, A y R16 poseen los mismos significados que anteriormente y R17 significa un átomo de halógeno o un resto de fórmula general VIII **(Fórmula)** de modo que puede ser igual a 0, 1 ó 2 (cuando p=0, se trata entonces de una amina acíclica primaria e Y porta un átomo de hidrógeno adicional), Y puede ser un átomo de carbono, oxígeno o nitrógeno y cuando Y es un átomo de carbono o nitrógeno, R18 significa un átomo de hidrógeno o un resto alquilo o **(Fórmula)** arilo, un resto alquilo o arilo sustituido, heterociclo, un resto alcoxicarbonilo, un resto aminocarbonilmetilo saturado o insaturado, o un resto aminocarbonilmetilo sustituido, R2 y R13 forman conjuntamente una unión de fórmula general IX o X **(Fórmula)** en las que W representa un átomo de carbono o nitrógeno, q puede adoptar un número entre 0 y 6 y R10 y R20 pueden significar átomos de hidrógeno, restos alquilo o alquilo sustituido, en las que R1, R7 y R12 son iguales o distintos y significan átomos de hidrógeno, restos alquilo y aminoalquilo, restos fenilsulfonilo, restos alquilsililmetoximetilo, un azúcar o un azúcar sustituido, en las que R3, R4, R5, R6, R8, R9, R10 y R11 son iguales o distintos y representan respectivamente un átomo de hidrógeno, un grupo alquilo, alcoxi, alcoximetilo sustituido con alcoxi, amino, halógeno, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo, un grupo nitro, un átomo de halógeno o un grupo O-alcoxi de fórmula general -O-(C=O)-R21, en la que R21 significa un grupo alquilo, alcoxi o alcoximetilo sustituido con alcoxi, amino, halógeno, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo.
ES99927711T 1998-05-04 1999-04-22 Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas. Expired - Lifetime ES2190221T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19819835 1998-05-04
DE19838506A DE19838506C2 (de) 1998-05-04 1998-08-25 Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen

Publications (1)

Publication Number Publication Date
ES2190221T3 true ES2190221T3 (es) 2003-07-16

Family

ID=26045937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99927711T Expired - Lifetime ES2190221T3 (es) 1998-05-04 1999-04-22 Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.

Country Status (21)

Country Link
US (2) US6407102B1 (es)
EP (1) EP1109785B1 (es)
JP (1) JP2002514572A (es)
CN (1) CN1151127C (es)
AT (1) ATE230394T1 (es)
AU (1) AU752464B2 (es)
BG (1) BG104996A (es)
BR (1) BR9911017A (es)
CA (1) CA2330756C (es)
CZ (1) CZ20003960A3 (es)
DE (1) DE59903921D1 (es)
DK (1) DK1109785T3 (es)
ES (1) ES2190221T3 (es)
HU (1) HUP0102563A3 (es)
IL (1) IL139056A0 (es)
NO (1) NO317261B1 (es)
NZ (1) NZ507735A (es)
PL (1) PL346840A1 (es)
SK (1) SK16352000A3 (es)
TR (1) TR200003206T2 (es)
WO (1) WO1999057117A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2190221T3 (es) 1998-05-04 2003-07-16 Zentaris Ag Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.
JP2002527419A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
US6719520B2 (en) 1998-10-08 2004-04-13 Smithkline Beecham Corporation Method and compounds
US6713505B2 (en) * 2000-06-28 2004-03-30 Eli Lilly And Company spla2 inhibitors
EP1310485A4 (en) * 2000-07-28 2005-07-20 Sumitomo Pharma Pyrrole derivatives
TW557298B (en) * 2000-08-14 2003-10-11 Ciba Sc Holding Ag A compound, a photopolymerizible composition, a process for producing coatings and a method for causing a photoinitiator to accumulate at the surface of coatings
US20030032625A1 (en) * 2001-03-29 2003-02-13 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors
DE10143079A1 (de) * 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
US20050267303A1 (en) * 2001-09-04 2005-12-01 Zentaris Ag Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals
EP1479384A1 (en) * 2002-01-30 2004-11-24 Sumitomo Pharmaceuticals Company, Limited Fibrosis inhibitor
US6800655B2 (en) 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2565387A1 (en) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
MX2008005661A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen.
CA2627353A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
US7666898B2 (en) * 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
WO2007056184A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
CA2627352A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
CN101704828A (zh) * 2009-11-04 2010-05-12 中国科学院昆明植物研究所 山橙素类双吲哚化合物,其药物组合物及其制备方法和用途
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN106317169B (zh) * 2015-06-23 2019-07-02 首都医科大学 双吲哚-二肽衍生物,其合成,抗血栓活性和制备抗血栓剂的应用
WO2018024172A1 (en) * 2016-08-05 2018-02-08 The University Of Hong Kong Platinum complexes and methods of use thereof
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2026006328A1 (en) * 2024-06-26 2026-01-02 Arizona Board Of Regents On Behalf Of Arizona State University Compositions and methods for mode-selective modulation of transient receptor potential vanilloid-1 (trpv1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598583A (en) * 1968-08-09 1971-08-10 Itek Corp Indomethylene dye bases and their utilization in photographic processes and compositions
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994024117A1 (fr) * 1993-04-22 1994-10-27 Nippon Shinyaku Co., Ltd. Derive de l'acide benzofurancarboxylique et composition pharmaceutique
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0817627T3 (da) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
JPH08295688A (ja) * 1995-04-28 1996-11-12 Sharp Corp ビスアゾ化合物、その中間体及びそれらの製造方法、並びにビスアゾ化合物を含有する電子写真感光体
DE19547263C2 (de) * 1995-12-07 1999-04-29 Cardiotec Inc Amidinohydrazone vom Benzo[b]furan abgeleiteter Ketone, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2190221T3 (es) 1998-05-04 2003-07-16 Zentaris Ag Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.

Also Published As

Publication number Publication date
WO1999057117A3 (de) 2001-04-12
TR200003206T2 (tr) 2001-07-23
HUP0102563A2 (hu) 2001-11-28
DK1109785T3 (da) 2003-04-22
US20030008898A1 (en) 2003-01-09
SK16352000A3 (sk) 2002-07-02
HK1038354A1 (en) 2002-03-15
JP2002514572A (ja) 2002-05-21
NO20005448D0 (no) 2000-10-27
HUP0102563A3 (en) 2003-04-28
CN1310705A (zh) 2001-08-29
CA2330756A1 (en) 1999-11-11
BG104996A (en) 2001-07-31
US6407102B1 (en) 2002-06-18
EP1109785A2 (de) 2001-06-27
NO317261B1 (no) 2004-09-27
PL346840A1 (en) 2002-02-25
NZ507735A (en) 2003-04-29
AU4497599A (en) 1999-11-23
BR9911017A (pt) 2001-02-06
IL139056A0 (en) 2001-11-25
CZ20003960A3 (cs) 2002-04-17
DE59903921D1 (de) 2003-02-06
CA2330756C (en) 2007-10-02
ATE230394T1 (de) 2003-01-15
EP1109785B1 (de) 2003-01-02
WO1999057117A2 (de) 1999-11-11
NO20005448L (no) 2000-10-27
AU752464B2 (en) 2002-09-19
CN1151127C (zh) 2004-05-26
US6812243B2 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
ES2220529T3 (es) Dibenzopiranos utiles como antagonistas del receptor de los glucocorticoides, en el tratamiento de la diabetes.
HRP20110498T1 (hr) Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
BR0213025A (pt) Compostos de espiro-hidantoìna úteis como agentes antiinflamatórios
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR040230A1 (es) Indol, azaindol, y heterociclos relacionados de 4-alquenil piperidina
HRP20040429B1 (hr) Derivati sulfonamida, njihova priprema i upotrebakao lijekova
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
AR053748A1 (es) Entidades quimicas, composiciones y metodos.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
NO954072L (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
AR003126A1 (es) Nuevos derivados de la camptotecina sustituidos que poseen actividad antitumoral, un procedimiento para su preparacion, y composicionesfarmaceuticas que los contienen.
NZ507735A (en) Indole derivatives useful for treating malignant and other diseases caused by pathological cell proliferation
UY24010A1 (es) Nuevos pirrolocarbazoles
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
ES2189941T3 (es) Derivados de nucleosidos aciclicos.
AR043563A1 (es) Inhibidores de catepsina s